O	0	17	Histopathological
O	18	28	assessment
O	29	31	of
B-intervention	32	43	anastrozole
O	44	47	and
B-control	48	57	tamoxifen
O	58	60	as
O	61	73	preoperative
O	74	75	(
O	75	86	neoadjuvant
O	86	87	)
O	88	97	treatment
O	98	100	in
O	101	115	postmenopausal
B-ethinicity	116	124	Japanese
O	125	130	women
O	131	135	with
O	136	143	hormone
O	144	152	receptor
O	152	153	-
O	153	161	positive
O	162	168	breast
O	169	175	cancer
O	176	178	in
O	179	182	the
O	183	189	PROACT
O	190	195	trial
O	195	196	.

O	197	200	The
O	201	213	PReOperative
O	214	215	'
O	215	223	Arimidex
O	223	224	'
O	225	233	Compared
O	234	238	with
O	239	248	Tamoxifen
O	249	250	(
O	250	256	PROACT
O	256	257	)
O	258	263	trial
O	264	272	compared
O	273	284	neoadjuvant
O	285	296	anastrozole
O	297	300	and
O	301	310	tamoxifen
O	311	313	in
B-eligibility	314	328	postmenopausal
I-eligibility	329	334	women
I-eligibility	335	339	with
I-eligibility	340	345	large
I-eligibility	345	346	,
I-eligibility	347	355	operable
I-eligibility	356	358	or
I-eligibility	359	370	potentially
I-eligibility	371	379	operable
I-eligibility	379	380	,
I-eligibility	381	388	locally
I-eligibility	389	397	advanced
I-eligibility	398	405	hormone
I-eligibility	406	414	receptor
I-eligibility	414	415	-
I-eligibility	415	423	positive
I-eligibility	424	430	breast
I-eligibility	431	437	cancer
O	437	438	.

O	439	443	Here
O	443	444	,
O	445	447	we
O	448	455	compare
O	456	465	objective
O	466	474	clinical
O	475	484	responses
O	485	489	with
O	490	507	histopathological
O	508	513	tumor
O	514	523	responses
O	524	526	to
O	527	534	therapy
O	535	537	in
O	538	539	a
O	540	546	cohort
O	547	549	of
B-total-participants	550	552	97
O	553	561	Japanese
O	562	570	patients
O	570	571	,
O	572	574	in
O	575	580	order
O	581	583	to
O	584	595	investigate
O	596	599	the
O	600	611	consistency
O	612	614	of
O	615	625	assessment
O	626	633	methods
O	634	637	and
O	638	641	the
O	642	648	change
O	649	651	in
O	652	660	estrogen
O	660	661	-
O	661	669	receptor
O	670	671	(
O	671	673	ER
O	673	674	)
O	675	678	and
O	679	691	progesterone
O	691	692	-
O	692	700	receptor
O	701	702	(
O	702	705	PgR
O	705	706	)
O	707	713	status
O	713	714	.

O	715	732	Histopathological
O	733	741	response
O	742	745	and
O	746	749	the
O	750	756	change
O	757	759	in
O	760	762	ER
O	763	766	and
O	767	770	PgR
O	771	777	status
O	778	782	were
O	783	791	assessed
O	792	794	by
O	795	804	comparing
O	805	817	pathological
O	818	827	specimens
O	828	837	collected
O	838	840	at
O	841	849	baseline
O	850	851	(
O	851	854	via
O	855	861	needle
O	862	868	biopsy
O	868	869	)
O	870	874	with
O	875	880	those
O	881	890	collected
O	891	893	at
O	894	895	3
O	896	902	months
O	903	904	(
O	904	908	from
O	909	916	excised
O	917	923	tumors
O	923	924	)
O	924	925	.

O	926	929	The
O	930	938	response
O	939	942	was
O	943	952	evaluated
O	953	958	using
O	959	971	Pathological
O	972	980	Response
O	981	989	Criteria
O	990	993	for
O	994	1000	Breast
O	1001	1007	Cancer
O	1008	1010	as
O	1011	1018	defined
O	1019	1021	by
O	1022	1025	the
O	1026	1034	Japanese
O	1035	1041	Breast
O	1042	1048	Cancer
O	1049	1056	Society
O	1056	1057	.

O	1058	1061	The
O	1062	1070	patients
O	1071	1075	were
O	1076	1086	randomized
O	1087	1089	to
O	1090	1097	receive
O	1098	1109	anastrozole
O	1110	1111	(
O	1111	1112	n
O	1113	1114	=
B-intervention-participants	1115	1117	48
O	1117	1118	)
O	1119	1121	or
O	1122	1131	tamoxifen
O	1132	1133	(
O	1133	1134	n
O	1135	1136	=
B-control-participants	1137	1139	49
O	1139	1140	)
O	1140	1141	.

O	1142	1143	A
O	1144	1155	numerically
O	1156	1163	greater
B-outcome	1164	1181	histopathological
I-outcome	1182	1190	response
I-outcome	1191	1195	rate
O	1196	1199	was
O	1200	1208	observed
O	1209	1213	when
O	1214	1225	neoadjuvant
O	1226	1237	anastrozole
O	1238	1246	compared
O	1247	1251	with
O	1252	1263	neoadjuvant
O	1264	1273	tamoxifen
O	1274	1275	(
B-iv-bin-percent	1275	1277	35
I-iv-bin-percent	1277	1278	.
I-iv-bin-percent	1278	1279	4
O	1280	1283	and
B-cv-bin-percent	1284	1286	12
I-cv-bin-percent	1286	1287	.
I-cv-bin-percent	1287	1288	2
I-cv-bin-percent	1288	1289	%
O	1289	1290	,
O	1291	1303	respectively
O	1303	1304	)
O	1304	1305	.

O	1306	1309	The
B-outcome	1310	1327	histopathological
I-outcome	1328	1331	and
I-outcome	1332	1340	clinical
I-outcome	1341	1350	objective
I-outcome	1351	1359	response
I-outcome	1360	1365	rates
O	1366	1372	agreed
O	1373	1375	in
O	1376	1378	63
O	1378	1379	/
O	1379	1381	97
O	1382	1390	patients
O	1390	1391	.

O	1392	1395	The
B-outcome	1396	1398	ER
I-outcome	1399	1405	status
O	1406	1408	of
B-iv-bin-abs	1409	1410	5
O	1410	1411	/
B-intervention-participants	1411	1413	40
O	1414	1422	patients
B-outcome	1423	1430	changed
I-outcome	1431	1435	from
I-outcome	1436	1444	positive
I-outcome	1445	1447	at
I-outcome	1448	1456	baseline
I-outcome	1457	1459	to
I-outcome	1460	1468	negative
I-outcome	1469	1471	at
I-outcome	1472	1473	3
I-outcome	1474	1480	months
O	1481	1483	in
O	1484	1487	the
O	1488	1499	anastrozole
O	1500	1505	group
O	1506	1514	compared
O	1515	1519	with
B-cv-bin-abs	1520	1522	20
O	1522	1523	/
B-control-participants	1523	1525	37
O	1526	1534	patients
O	1535	1537	in
O	1538	1541	the
O	1542	1551	tamoxifen
O	1552	1557	group
O	1557	1558	.

O	1559	1562	The
B-outcome	1563	1566	PgR
I-outcome	1567	1573	status
O	1574	1576	of
B-iv-bin-abs	1577	1579	16
O	1579	1580	/
B-intervention-participants	1580	1582	17
O	1583	1591	patients
O	1592	1594	in
O	1595	1598	the
O	1599	1610	anastrozole
O	1611	1616	group
O	1617	1620	and
O	1621	1623	of
B-cv-bin-abs	1624	1625	1
O	1625	1626	/
B-control-participants	1626	1628	11
O	1629	1637	patients
O	1638	1640	in
O	1641	1644	the
O	1645	1654	tamoxifen
O	1655	1660	group
B-outcome	1661	1668	changed
I-outcome	1669	1673	from
I-outcome	1674	1682	positive
I-outcome	1683	1685	to
I-outcome	1686	1694	negative
O	1694	1695	.

O	1696	1701	These
O	1702	1706	data
O	1707	1714	support
O	1715	1718	the
O	1719	1727	findings
O	1728	1730	of
O	1731	1734	the
O	1735	1739	main
O	1740	1746	PROACT
O	1747	1752	trial
O	1752	1753	,
O	1754	1759	which
O	1760	1769	confirmed
O	1770	1774	that
O	1775	1786	anastrozole
O	1786	1787	,
O	1788	1790	as
O	1791	1799	compared
O	1800	1804	with
O	1805	1814	tamoxifen
O	1814	1815	,
O	1816	1818	is
O	1819	1821	an
O	1822	1831	effective
O	1832	1843	neoadjuvant
O	1844	1853	endocrine
O	1854	1863	treatment
O	1864	1866	in
O	1867	1876	objective
O	1877	1885	response
O	1886	1891	rates
O	1892	1895	for
O	1896	1910	postmenopausal
O	1911	1916	women
O	1917	1921	with
O	1922	1927	large
O	1928	1936	operable
O	1937	1944	hormone
O	1944	1945	-
O	1945	1953	receptor
O	1954	1962	positive
O	1963	1969	breast
O	1970	1976	cancer
O	1976	1977	.

O	1978	1985	Further
O	1986	1992	follow
O	1992	1993	-
O	1993	1995	up
O	1996	1998	is
O	1999	2007	required
O	2008	2010	to
O	2011	2018	confirm
O	2019	2026	whether
O	2027	2044	histopathological
O	2045	2054	responses
O	2055	2057	to
O	2058	2065	therapy
O	2066	2075	correlate
O	2076	2080	with
O	2081	2083	an
O	2084	2091	overall
O	2092	2103	improvement
O	2104	2106	in
O	2107	2115	survival
O	2115	2116	.
